Last mentioned: Mar 24, 2026
Compliance Review
Industry analysts begin evaluating the impact on ImmunityBio's internal promotional controls.
FDA Warning Issued
Federal health officials issue a formal warning over misleading statements made by Patrick Soon-Shiong.
Media Reports
Major outlets including Seattle Times and MedPage Today report on the regulatory crackdown.
The FDA has issued a formal warning to billionaire Patrick Soon-Shiong regarding misleading promotional statements about ImmunityBio’s bladder cancer treatment. The regulatory action highlights a growing crackdown on off-label marketing conducted through non-traditional media channels like podcasts.
This page surfaces every story mentioning ImmunityBio across our legal coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running legal beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where ImmunityBio was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |